Clinical Trials on Autoimmune Hepatitis in Austria

Total 1270 results

Vertex Pharmaceuticals Incorporated

Terminated

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype (CONCISE)

Hepatitis C, Chronic

United States, Austria, Canada, Germany, Israel, Poland
Medical University of Graz

Completed

Incretin Effect on the Immunological Phenotype

Type 1 Diabetes

Austria
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico, Australia
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Medical University of Vienna
National Bank of Austria

Unknown

Interventions to Prevent Adolescents With Type 1 Diabetes From Long-term Complications

Diabetes Mellitus, Type 1

Austria
Novaliq GmbH

Completed

Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease

Dry Eye Disease

Austria
University of Texas at Austin

Unknown

Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis

Multiple Sclerosis

United States
Suzhou Connect Biopharmaceuticals, Ltd.
Tigermed Consulting Co., Ltd; Nucleus Network Ltd

Completed

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

Autoimmune Diseases

Australia
AbbVie

Completed

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Hepatitis C

Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
Medical University of Vienna

Completed

Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects

Dry Eye Syndrome

Austria
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
Medical University of Vienna

Completed

Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects

Type I Diabetes

Austria
Arecor Limited

Completed

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Diabetes Mellitus, Type 1

Austria
University of Texas at Austin

Completed

A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology (PALMS-II)

Multiple Sclerosis

United States
Janssen R&D Ireland

Completed

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Hepatitis C

United States, Australia, France, Ukraine, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Bulgaria, Netherlands, Canada, New Zealand, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Poland, Romania, Mexico
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

China, Hong Kong, Australia, Germany, Taiwan, Singapore, France, United States, Korea, Republic of, New Zealand, Thailand, Russian Federation, Brazil
Novo Nordisk A/S

Completed

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works

Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, United Kingdom, Austria, Italy
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
Medical University of Graz
Menarini Group

Completed

Accuracy, Reliability and Safety of GlucoMen®Day, a New Generation Microdialysis Continuous Glucose Monitor

Type 1 Diabetes

Austria
Medical University of Vienna

Recruiting

Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Withdrawn

Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease

Dry Eye Syndrome

Austria
Medical University of Vienna

Completed

Correlation of Different Signs for Assessment of Dry Eye Syndrome

Dry Eye Syndrome

Austria
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)

Hepatitis D, Chronic

France, Taiwan, Italy, Germany, Japan, Spain, Russian Federation, Turkey, United Kingdom, Australia, Sweden, United States, New Zealand, China, Brazil
Novartis Pharmaceuticals

Completed

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Hepatitis | Hepatitis B, Chronic | Cirrhosis

United States, France, United Kingdom, Taiwan, Spain, Korea, Republic of, Singapore, New Zealand, Thailand, Germany, Israel, Russian Federation, Canada, China, Latvia, Turkey, Australia, India, Malaysia, Poland, Vietnam
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain
Novo Nordisk A/S

Completed

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Gilead Sciences

Completed

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Hepatitis C Virus Infection

Germany, United States, Australia, United Kingdom, Canada, France, New Zealand
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

United States, Puerto Rico
Medical University of Graz
Medical University of Vienna

Completed

Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes

Type 1 Diabetes

Austria
Medical University of Graz
Menarini Group

Completed

Performance Study to Test the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes

Type 1 Diabetes

Austria
Landsteiner Institut
University of Coimbra

Completed

Non Invasive Assessment of Liver Glycogen Kinetics and ATP Synthesis in Type1 Diabetics

Type 1 Diabetes Mellitus

Austria
Tibotec Pharmaceuticals, Ireland

Completed

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (ASPIRE)

Hepatitis C

United States, Australia, France, United Kingdom, Belgium, Germany, Israel, Portugal, Canada, New Zealand, Russian Federation, Austria, Poland, Norway
Biogen

Terminated

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose (TODAY)

Relapsing Remitting Multiple Sclerosis

Australia

3

Subscribe